PDF( 8mb) - Malaysian Dental Association

Are COX-2 inhibitors a solution to problems associated with current oral analgesics? A revisit with a perspective of local need.formulation and a standard release formulation after thirdmolar surgery: a randomised controlled trial. Br Dent J. 2001;191: 319-24.64. Stoelting PK. Pharmacology & Physiology in AnestheticPractice. 1999. 3rd ed. Lippincott Williams & Wilkins,Philadelphia.65. Malmstrom K, Daniels S, Kotey P, Seidenberg BC,Desjardins PJ. Comparison of rofecoxib and celecoxib, twocyclooxygenase-2 inhibitors, in postoperative dental pain:a randomised placebo- and active- comparator controlledclinical trial. Clin Ther. 1999; 21: 1653-63.66. Daniels SE, Desjardins PJ, Talwalker S, Recker DP, VerburgKM. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc. 2002;133: 611-62.67. Doyle G, Jayawardena S, Ashraf E, Cooper SA. Efficacy andtolerability of non-prescription ibuprofen versus celecoxibfor dental pain. J Clin Pharmacol. 2002; 42: 912-9.68. Khan AA, Brahim JS, Rowan JS, Dionne RA. In vivoselectivity of a selective cyclooxygenase 2 inhibitor in theoral surgery model. Clin Pharmacol Ther. 2002; 72: 44-9.69. Malmstrom K, Fricke JR, Kotey P, Kress B, Morrison B. Acomparison of rofecoxib versus celecoxib in treating painafter dental surgery: a single-center, randomized, doubleblind,placebo- and active-comparator-controlled, parallelgroup,single-dose study using the dental impaction model.Clin Ther. 2002; 24: 1549-60.70. Fricke J, Varkalis J, Zwillich S, Alder R, Forester E, ReckerDP, Verburg KM. Valdecoxib is more efficacious thanrofecoxib in relieving pan associated with oral surgery. Am JTher. 2002; 9: 89-97.71. Christensen, K. S., Cawkwell, G. D. (2004). Valdecoxib versusrofecoxib in acute postsurgical pain: results of a randomizedcontrolled trial. J Pain Symptom Manage 27, 460-470.72. Zelenakas K, Fricke JR, Jaywardene S, Kellstein D. Analgesiceffect of single oral doses of lumiracoxib and ibuprofen inpatients with postoperative dental pain. Int J Clin Pract. 2004;58: 251-6.73. Kellstein D, Ott D, Jayawardene S, Fricke J. Analgesicefficacy of a single dose of lumirocoxib compared torofecoxib, celecoxib and placebo in the treatment of postoperativedental pain. Int J Clin Pract. 2004; 58: 244-50.74. Chang DJ, Desjardins PJ, King TR, Erb T, Geba GP. Theanalgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: arandomized, double-blind clinical trial. Anesth Analg. 2004;99: 807-15. Erratum in: Anesth Analg. (2005), 101, 644.75. Malmstrom K, Kotey P, Coughlin H, Desjardins PJ. Arandomized, double-blind, parallel-group study comparing theanalgesic effect of etoricoxib to placebo, naproxen sodium,and acetaminophen with codeine using the dental impactionpain model. Clin J Pain. 2004; 20: 147-155.76. Malmstrom K, Sapre A, Couglin H, Agrawal NG, MazenkoRS, Fricke JR Jr. (). Etoricoxib in acute pain associated withdental surgery: A randomized, double-blind, placebo- andactive comparator–controlled dose-ranging study. Clin Ther.2004; 26: 667-79.77. Malmstrom K, Ang J, Fricke JR, Shingo S, Reicin A. Theanalgesic effect of etoricoxib relative to that of cetaminophenanalgesics: a randomized, controlled single-dose study inacute dental impaction pain. Curr Med Res Opin. 2005; 21:141-9.78. Chalini S, Raman U. Comparative efficacy of aceclofenacand etoricoxib in post extraction pain control: randomizedcontrol trial. Ind J Dent Res. 2005; 16: 47-50.79. Toivonen J, Pitko VM, Rosenberg PH. Etoricoxib premedicationcombined with intra-operative subacromial blockfor pain after arthroscopic acromioplasty. Acta AnaesthesiolScand. 2007; 51: 316-21.80. Puura A, Puolakka P, Rorarius M, Salmelin R, LindgrenL. Etoricoxib pre-medication for post-operative pain afterlaparoscopic cholecystectomy. Acta Anaesthesiol Scand.2006; 50: 688-93.81. Liu W, Loo CC, Tan HM, Ye TH, Ren HZ. Comparisonof preemptive analgesia efficacy between etoricoxib androfecoxib in ambulatory gynecological surgery. Zhongguo YiXue Ke Xue Yuan Xue Bao. 2004; 26: 666-70.82. Muratore L, Ventura M, Calogiuri G, Calcagnile F, QuartaE, Muratore M, Ferrannini A. Tolerance to etoricoxib in37 patients with urticaria and angioedema induced bynonsteroidal anti-inflammatory drugs. Ann Allergy AsthmaImmunol. 2007; 98: 168-71.83. Viola M, Quaratino D, Gaeta F, Caruso C, Valluzzi R, RomanoA. Etoricoxib tolerability in patients with hypersensitivityto nonsteroidal anti-inflammatory drugs. Int Arch AllergyImmunol. 2007; 143: 103-8.84. El Miedany Y, Youssef S, Ahmed I, El Gaafarym M. Safety ofetoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmaticpatients with aspirin-exacerbated respiratory disease. AnnAllergy Asthma Immunol. 2006; 97: 105-9.85. Chan VS. A mechanistic perspective on the specificity andextent of COX-2 inhibition in pregnancy. Drug Saf. 2004; 27:421-6.86. Cicconetti A, Bartoli A, Ripari F, Ripari A. Cox-2 selectiveinhibitors: A literature review of analgesic efficacy and safetyin oral-maxillofacial surgery. Oral Surg Oral Med Oral PatholOral Radiol Endod 2004; 97: 139-46.87. Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitorsvs non-selective NSAIDs: does their cardiovascular riskexceed their gastrointestinal benefit? A retrospective cohortstudy. Rheumatology (Oxford) 2007; 46: 435-8.88. Schellenberg RR, Isserow SH. Anaphylactoid reaction to acyclooxygenase-2 inhibitor in a patient who had a reactionto a cyclooxygenase-1 inhibitor. N Engl J Med. 2001; 345:1856.89. Augustine M, Sharma P, Stephen J, Jayaseelan E. Fixed drugeruption and generalised erythema following etoricoxib.Indian J Dermatol Venereol Leprol. 2006; 72: 307-9.90. Wiholm BE. Identification of sulfonamide-like adverse drugreactions to celecoxib in the World Health Organizationdatabase. Curr Med Res Opin. 2001; 17: 210-6.92